SightLine raises $107M fund for med tech investments

Minnesota's SightLine Partners has $107 million and an eye out for promising late-stage medical technology companies. SightLine plans to use its oversubscribed second fund to provide creative financing options for device and diagnostics outfits working to get novel technologies to market. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.